0

Global Lymphoma Drugs Market 2017-2021

  • Published: Jun 2017
  • Pages: 70
  • SKU: IRTNTR12892
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study identifies Celgene, F. Hoffmann-La Roche, Johnson & Johnson, and Seattle Genetics as the leading players in the global lymphoma drugs market. A comprehensive analysis of this market is also presented by disease type (HL drugs market and NHL drugs market) and by geography (the Americas, APAC, and EMEA).

Overview of the global lymphoma drugs market

According to lymphoma drugs industry analysis, the global lymphoma drugs market will grow at a CAGR of more than 8% during the forecast period. The growing trend for industry-academia collaborations will drive the growth prospects for the market during the projected period. Key players are increasingly supporting academic institutions by heavily investing in research and developmental activities to develop innovative drugs. This allows the integration of the research expertise of academic institutions with the marketing intelligence of pharmaceutical companies. For instance, Merck's cancer segment supported the development of monoclonal antibodies (mAbs) for cancer by collaborating with academic institutions such as BioMed X. Similarly, Takeda Pharmaceuticals and National Cancer Center of Japan promoted the exchange of physicians and researchers engaged in cancer biology research and anticancer drug discovery to conduct basic research and clinical developments.

The development of rituximab resistance that will result in the emergence of new therapies will be one of the major factors that will gain traction in the lymphoma drugs market during the next four years. Rituximab is used for the treatment of lymphoma and other autoimmune diseases. With the use of this drug in combination with other drugs or alone as the first line treatment of B-cell lymphomas its popularity will increase in the coming years as well. Such development will emerge as major breakthroughs in the treatment of lymphoma, subsequently driving the market’s growth prospects.

Competitive landscape and key vendors

The global lymphoma drugs market is characterized by the presence of many vendors across the globe. These vendors are increasingly competing against each other based on factors such as rich pipeline, emerging indications or applications, and collaborations. Vendors are increasingly focusing on boosting the survival rate and reducing the mortality rate by heavily investing in research and developmental activities in the lymphoma drugs market. Factors such as the growing pipeline and development of alternative drugs will intensify the market’s competitive environment.

Key vendors in this market are 

  • Celgene
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Seattle Genetics

Other prominent vendors in the market include Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.

Segmentation by disease type and analysis of the lymphoma drugs market

  • HL drugs market
  • NHL drugs market

The non-hodgkin lymphoma (NHL) drugs segment dominated the lymphoma drugs market during 2016. NHL is a type of cancer that begins in the lymphocytes. The reed-sternberg B-cell in NHL cancer cannot be seen under the microscope. The NHL segment is driven by the high prevalence of diseases, especially in the North American and European countries. This drives the occurrence of MALT lymphoma, MCL, adult T-cell leukemia or lymphoma, and natural killer T-cell lymphoma, which will fuel the adoption of NHL drugs during the next four years.

Segmentation by geography and analysis of the lymphoma drugs market

  • Americas
  • APAC
  • EMEA

Based on the lymphoma drugs industry insights, the Americas was the major revenue contributor to the lymphoma drugs market during 2016. Lymphoma accounts for around 5% of the total cancer cases in the US. It has been observed that in Canada, lymphoma is the most common form of cancer in children after leukemia and cancer cases related to the central nervous system (CNS).

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global lymphoma drugs market?
  • What are the key market trends impacting the growth of the global lymphoma drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global lymphoma drugs market?
  • What are the market opportunities and threats faced by the vendors in the global lymphoma drugs market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global lymphoma drugs market?

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline
  • Lymphoma disease overview

PART 05: Market Introduction

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by disease type

  • HL
  • NHL

PART 08: Geographical segmentation

  • Lymphoma drugs market in Americas
  • Lymphoma drugs market in EMEA
  • Lymphoma drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Increasing consolidation in the cancer treatment market
  • Development of rituximab resistance leading to the development of new therapies
  • Studies performed to understand the genetics of lymphoma cells

PART 12: Vendor landscape

  • Competitive scenario

PART 13: Key vendor analysis

  • Celgene
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Seattle Genetics
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>